Bausch Health Announces VYZULTA® , 0.024%, is Now Approved In Seven Countries Medical Device Investing
IDEAYA and Pfizer Expand Clinical Trial Collaboration and Supply Agreement to Evaluate Clinical Combination of IDE196 and Crizotinib in Solid Tumors Harboring GNAQ or GNA11 Mutations Pharmaceutical Investing
Javelin Biotech Aims to Develop Industry-Leading "Organ-on-a-Chip" Predictive Pharmacokinetics Platform in Collaboration with Pfizer Inc. Pharmaceutical Investing
FDA Accepts Supplemental New Drug Application for Pfizer's XALKORI® for the Treatment of Pediatric ALK-positive Anaplastic Large Cell Lymphoma Pharmaceutical Investing
Johnson & Johnson Initiates Pivotal Global Phase 3 Clinical Trial of Janssen's COVID-19 Vaccine Candidate Medical Device Investing
Pfizer Invites Public to View and Listen to Webcast of October 27 Conference Call with Analysts Pharmaceutical Investing
Algernon Announces 50% Enrollment in Multinational 2b/3 Human Study of Ifenprodil for Treatment of COVID-19 Biotech Investing
Bausch Health And Alfasigma Announce Resolution Of XIFAXAN® Intellectual Property Litigation Medical Device Investing
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb and bluebird bio Application for Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel Biotech Investing
